Internal Medicine

Can a Simple Blood Test Diagnose Severe CTE During Life?

Published on Nov 20, 2026
3 min read
Can a Simple Blood Test Diagnose Severe CTE During Life? - OC Academy Medical Insights
"Discover how plasma eMTBR-tau serves as a novel blood biomarker detecting high-stage chronic traumatic encephalopathy tau tangle pathology during life."

Diagnosing chronic traumatic encephalopathy during life remains one of modern neurology's most formidable clinical challenges. Consequently, clinicians must currently rely on postmortem neuropathological evaluation to establish a definitive diagnosis. However, new research identifies plasma eMTBR-tau as a promising fluid biomarker for detecting neuropathology in living patients. Investigators evaluated endogenously cleaved microtubule-binding region tau in plasma samples from former contact sport athletes. Therefore, this discovery represents a critical milestone toward routine in vivo detection of neurodegenerative tauopathies.

Evaluating Plasma eMTBR-tau in CTE Neuropathology

The case series investigated 21 deceased brain donors who had provided ante-mortem plasma specimens. Specifically, neuropathologists confirmed a diagnosis of chronic traumatic encephalopathy in 18 of these donors. Among these individuals, 16 brain donors exhibited advanced high-stage disease, comprising stage III and IV pathology. Furthermore, laboratory assays demonstrated markedly elevated plasma concentrations of this biomarker in donors with confirmed disease. In contrast, donors without tau tangle pathology displayed negligible baseline concentrations of the protein fragment. Statistical analyses confirmed that higher plasma levels strongly correlated with total brain tau burden scores. Thus, the biomarker directly reflects cerebral tau tangle accumulation across multiple vulnerable brain regions.

Differentiating High-Stage CTE from Alzheimer Copathology

Clinical differentiation between pure traumatic tauopathy and comorbid Alzheimer neuropathology presents significant diagnostic hurdles. Notably, five donors in the study cohort harbored concomitant intermediate or high Alzheimer disease neuropathologic change. Patients with dual pathology demonstrated the highest biomarker concentrations among all examined cases. However, significant biomarker elevations persisted even after researchers completely excluded all cases with Alzheimer changes. Meanwhile, plasma phosphorylated tau 217 correlated with the novel biomarker but failed to track disease presence. Consequently, pairing these two distinct assays may offer complementary diagnostic clarity in complex cognitive presentations.

Clinical Relevance and Future Diagnostic Utility

Repetitive head impacts occur frequently in contact sports, road traffic collisions, and physical assaults worldwide. Therefore, establishing accurate fluid biomarkers holds immense relevance for practicing neurologists, neurosurgeons, and sports physicians. Early biological detection will assist clinicians in differentiating chronic trauma sequelae from unrelated neurodegenerative disorders. In addition, validated blood assays could accelerate enrollment into prospective neuroprotective clinical trials. Nonetheless, researchers emphasize that larger clinical cohorts must validate diagnostic thresholds before routine adoption. Ultimately, these promising findings pave the way for precise biomarker-driven management in vulnerable patient groups.

Frequently Asked Questions

Q1: What is plasma eMTBR-tau and what does it measure?

Plasma eMTBR-tau measures endogenously cleaved microtubule-binding region tau fragments in peripheral blood. It reflects insoluble tau tangle neuropathology accumulating in cerebral tissue during neurodegenerative processes.

Q2: Can doctors currently use this blood test in routine clinical practice?

No, the assay currently serves strictly as a specialized clinical research tool. Researchers must conduct larger multicentre validation trials before regulatory agencies approve the test for routine clinical diagnosis.

Q3: How does this biomarker differ from plasma p-tau217?

Plasma p-tau217 primarily tracks amyloid-driven tau phosphorylation characteristic of Alzheimer disease. In contrast, plasma eMTBR-tau directly correlates with high-stage tau tangles in chronic traumatic encephalopathy even without Alzheimer pathology.

References

  1. Miner AE et al. Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology. JAMA. 2026 Nov 19. doi: 10.1001/jama.2026.24780. PMID: 43056497.
  2. Palleis C, Höglinger GU. Plasma eMTBR-tau as a potential biomarker across tauopathies. JAMA. 2026. doi: 10.1001/jama.2026.24588.
  3. Horie K et al. Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology. JAMA. 2026. doi: 10.1001/jama.2026.24689.

Related Articles You May Like